That reflected a decrease from $189.8 million at the end of 2016. Celldex thinks that its cash position, combined with anticipated proceeds from future sales of its stock under an existing agreement, will fund operations through 2018. This …
KeyBank
Now that we’ve mentioned the most bullish investors, let’s also take a look at some funds that cut their entire stakes in the stock during the third quarter. Interestingly, First Eagle Investment Management cut the biggest position of all the …
Celldex Therapeutics is having a horrible day in the market today, and for a very good reason. The company has announced that it is discontinuing a clinical trial that has long been in the works and investors are very disappointed. …
There has been a significant rally in the share price of Celldex (NASDAQ: CLDX) recently. The stock is still showing positive momentum due to strong data on its drug trials. This positive data makes the company an attractive target for …
CLDX) with a price target of $3.50. There are 2 hold ratings, 6 buy ratings on the stock. The current consensus rating on Celldex Therapeutics (NASDAQ:CLDX) is Buy (Score: 2.75) with a consensus target price of $8.07 per share, a …
NASDAQ
This decrease was partially offset by the receipt of $12.8 million from sales of our common stock under our Cantor agreement. At March 31, 2017, Celldex had 124.2 million shares outstanding. Revenues: Total revenue was $1.5 …
NASDAQ
Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced that the Company has entered into a definitive agreement to …
NASDAQ